Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024 12:26 ET
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; August 26, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will...
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
August 19, 2024 14:00 ET
|
Genmab A/S
Company Announcement TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma...
Genmab Announces Changes to its Executive Committee
August 16, 2024 09:00 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; August 16, 2024 Rayne Waller joins as Executive Vice President and Chief Technology OfficerBrad Bailey appointed as Executive Vice President and Chief...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
August 13, 2024 14:53 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
August 13, 2024 14:51 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,193 shares as a consequence of the exercise of employee warrants. The...
Genmab Announces Financial Results for the First Half of 2024
August 08, 2024 11:03 ET
|
Genmab A/S
August 8, 2024 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2024 Highlights Completed acquisition of ProfoundBio Inc (ProfoundBio), granting Genmab worldwide rights to...
Genmab Updates 2024 Financial Guidance
August 08, 2024 11:00 ET
|
Genmab A/S
Company Announcement Genmab updates its 2024 financial guidanceIncrease in revenue driven by higher royalties and reimbursement revenueIncrease in operating profit excluding acquisition and...
Genmab Takes Full Control of Acasunlimab Development Program
August 05, 2024 05:50 ET
|
Genmab A/S
Company Announcement Genmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab BioNTech has opted not to participate in the further development...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
July 17, 2024 06:25 ET
|
Genmab A/S
Company Announcement Net sales of DARZALEX® in the second quarter of 2024 totaled USD 2,878 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,...
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
June 28, 2024 02:00 ET
|
Genmab A/S
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE® NHL-1 studyFL is the second most common type of NHL and accounts for approximately 20-30 percent of all global...